Transfusion medicine

Vitalant Unveils Innovation Center, First-of-its-Kind in the U.S.

Retrieved on: 
Thursday, August 10, 2023
Microsoft Innovation Center, Science, Innovation Center station, Research institute, Research, World War II, Doctor of Philosophy, Patient, Transfusion medicine, Medical device, Vitalant

DENVER, Aug. 10, 2023 /PRNewswire/ -- As one of the nation's largest nonprofit blood and biotherapies providers, Vitalant unveiled its new Denver-based Innovation Center in a ribbon-cutting ceremony Wednesday. A first of its kind in the U.S., the Vitalant Innovation Center is where innovative blood center equipment and processes can be tested outside of normal operations, advancing the science of transfusion medicine and research.

Key Points: 
  • DENVER, Aug. 10, 2023 /PRNewswire/ -- As one of the nation's largest nonprofit blood and biotherapies providers, Vitalant unveiled its new Denver-based Innovation Center in a ribbon-cutting ceremony Wednesday.
  • A first of its kind in the U.S., the Vitalant Innovation Center is where innovative blood center equipment and processes can be tested outside of normal operations, advancing the science of transfusion medicine and research.
  • "The Vitalant Innovation Center represents our commitment to forging advancements in transfusion medicine to help save and sustain more lives."
  • "The Innovation Center provides a much-needed 'sandbox' to advance cutting-edge developments and bring new products to Vitalant and the blood services industry," Susanne Marschner, Ph.D., Vitalant Innovation Center vice president of research and scientific programs, said.

QuidelOrtho Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Health, Biotechnology, Transfusion medicine, QuidelOrtho, GAAP, LPS, Interest, EBITDA, Webcast, Growth, EPS, Conference, Labs, Medical device, Video game, Online shopping

The Company reported total revenue for the second quarter of 2023 of $665.1 million, compared to $613.4 million for the second quarter of 2022.

Key Points: 
  • The Company reported total revenue for the second quarter of 2023 of $665.1 million, compared to $613.4 million for the second quarter of 2022.
  • GAAP operating loss for the second quarter of 2023 was $(26.9) million, compared to operating income of $79.7 million for the second quarter of 2022, and GAAP operating margin was (4)% and 13% for the second quarters of 2023 and 2022, respectively.
  • Adjusted diluted EPS for the second quarter of 2023 decreased to $0.26, compared to $2.12 for the second quarter of 2022.
  • Adjusted EBITDA margin for the second quarter of 2023 was 17.0%, compared to 32.4% for the second quarter of 2022.

European Extracellular Vesicles & Nanoparticle-based Therapeutics Conference 2023: Explore Cutting-Edge Innovations and Therapeutic Opportunities (Rotterdam, Netherlands - November 13-14, 2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Technology, Hospitals, Science, Surgery, Nanotechnology, Biotechnology, Other Science, Health, EV, University, Exhibition, Engineering, Associate professor, University Medical Center, Head, Therapy, Eurostar, University of Bordeaux, Medical biology, Teaching hospital, Seminal vesicles, A*STAR, Transfusion medicine, Faculty, Nanoparticle, International Society for Extracellular Vesicles, Vaccine, Conference, Medical device, Management, Pharmaceutical industry, Hospital, Nanomedicine

The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles (EV) & Nanoparticle-based Therapeutics Europe 2023 Conference to be held 13-14 November 2023 at the Hilton Rotterdam, The Netherlands.
  • At this conference we bring together speaking faculty who represent academic thought leaders as well as leading industry participants translating technologies into commercial offerings and innovations in the field.
  • The conference features extensive networking opportunities and is held 7-minutes walk from Rotterdam Centraal with fast and very easy access to Amsterdam-Schiphol with worldwide connections as well as the Eurostar to London plus fast-trains to Antwerp, Brussels and Paris.

QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings

Retrieved on: 
Tuesday, July 25, 2023
General Health, Health, Data Management, Technology, Software, Data management, Informatics, Workflow, Partnership, QuidelOrtho, Laboratory, Transfusion medicine, Medical device

“Our partnership with BYG4lab® reaches across the business, from clinical labs to transfusion medicine to point-of-care, and it allows QuidelOrtho to rapidly integrate affordable, cutting-edge and time-saving informatics solutions,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.

Key Points: 
  • “Our partnership with BYG4lab® reaches across the business, from clinical labs to transfusion medicine to point-of-care, and it allows QuidelOrtho to rapidly integrate affordable, cutting-edge and time-saving informatics solutions,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.
  • This partnership reflects QuidelOrtho’s appreciation of the importance of informatics to today’s labs and the Company’s determination to create robust solutions that are agile and can be updated quickly and easily to support our customers’ needs.
  • “With ever-increasing testing demands and decreasing staffing availability, accurate and automated record collection and management are critical to assuring the highest quality of patient care,” Mr. Bryant noted.
  • “QuidelOrtho is committed to provide integrated diagnostics systems and informatics solutions that bridge the gap and give our customers an edge.”

European Extracellular Vesicles & Nanoparticle-based Therapeutics Conference 2023: Advancing Therapeutics - Industry Giants and Academic Experts Converge (Rotterdam, Netherlands, November 13-14, 2023)

Retrieved on: 
Monday, July 24, 2023
EV, University, Exhibition, Engineering, Associate professor, University Medical Center, Head, Therapy, Eurostar, University of Bordeaux, Medical biology, Teaching hospital, Seminal vesicles, A*STAR, Transfusion medicine, Faculty, Nanoparticle, Research, International Society for Extracellular Vesicles, Vaccine, Conference, Management, Pharmaceutical industry, Hospital, Nanomedicine

DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles (EV) & Nanoparticle-based Therapeutics Europe 2023 Conference to be held 13-14 November 2023 at the Hilton Rotterdam, The Netherlands.
  • At this conference we bring together speaking faculty who represent academic thought leaders as well as leading industry participants translating technologies into commercial offerings and innovations in the field.
  • This conference features scientific presentations, industry technology spotlight presentations, posters as well as a co-located exhibition, and the conference features companies in this field developing technologies, products and services as well as moving (clinical) candidates forward into the clinical trials regimen.

QuidelOrtho to Report Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, July 18, 2023
General Health, Health Technology, Health, Medical Supplies, Interest, Webcast, QuidelOrtho, Conference, Transfusion medicine, Online shopping

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2023 ended July 2, 2023, after the market close on Tuesday, August 8, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2023 ended July 2, 2023, after the market close on Tuesday, August 8, 2023.
  • Following the release of the financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m.
  • ET to discuss its financial results.
  • Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/ .

 Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Retrieved on: 
Saturday, June 24, 2023
Entertainment, Health, Film & Motion Pictures, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Natural history study, PK, Red, Pregnancy, Bleeding, Half-life, RHD (gene), SC, Fetus, European Medicines Agency, Woman, Congress, Corporation, Patient, Intracranial hemorrhage, Data, Risk, Webcast, Transfusion medicine, Thrombosis, Ageing, Rare, Regulation of tobacco by the U.S. Food and Drug Administration, International Society, Food, Pharmaceutical industry, Dietary supplement, Copper, ISTH

Mean platelet elimination half-life was 5.8 hours (0.09mg) and 1.5 hours (0.29mg) for RLYB212 compared to 71.7 hours for placebo.

Key Points: 
  • Mean platelet elimination half-life was 5.8 hours (0.09mg) and 1.5 hours (0.29mg) for RLYB212 compared to 71.7 hours for placebo.
  • The study included 11 males aged 18 to 65 years, randomized to RLYB212 0.09mg (n=4), RLYB212 0.29mg (n=5), or placebo (n=2).
  • Rallybio will host an investor and analyst meeting on Saturday, June 24, 2023 from 4:00 to 6:00 p.m. Eastern Time.
  • The webcast and corresponding slides can be accessed through the Events and Presentations section of Rallybio’s website at http://www.rallybio.com .

Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress

Retrieved on: 
Thursday, June 15, 2023
Medical Supplies, Health, Hospitals, Other Health, Pharmaceutical, Biotechnology, Abstract, Transfusion medicine, CET, Comparison, Stanford University, Best current practice, Congress, International Practice Management Association, Corporation, Patient safety, CERS, ISBT, Vaccine, Cerus Corporation

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21.
  • Transfusion medicine experts and professionals from around the world attend the ISBT Congress.
  • This year marks the first time the conference has taken place in person since 2019.
  • The following is a select list of presentations and abstracts of interest for Cerus.

Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis

Retrieved on: 
Friday, June 9, 2023
Research, Finance, Public Relations, Investor Relations, Communications, Professional Services, Other Health, Biotechnology, General Health, Health, Science, Q&A, Congress, Corporation, Patient, Webcast, Transfusion medicine, Thrombosis, Neonatal alloimmune thrombocytopenia, Rare, Coil Presents Time Machines, International Society, Pharmaceutical industry, Communications satellite, ISTH

RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Key Points: 
  • RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
  • Data from the Phase 1b RLYB212 proof-of-concept study will be presented by Christof Geisen, M.D., as an oral presentation.
  • The meeting will include a presentation of the data from the RLYB212 Phase 1b Proof-Of-Concept Study by Dr. Geisen, and a corporate discussion on the RLYB212 development program.
  • The meeting will be webcast and can be accessed through the Events and Presentations section of Rallybio’s website at http://www.rallybio.com .

Vivante Adds Key Corporate Clients for GIThrive Digital Health Platform

Retrieved on: 
Tuesday, June 6, 2023
Soma, Workforce, Vivante Corporation, Grifols, Health, Transfusion medicine, Absenteeism, Quality of life, FAS, Organization, White House Black Market, Mass media, Growth, Transport, Trauma, Mental health, Health insurance, Consultant

CHICAGO, June 6, 2023 /PRNewswire/ -- Vivante Health, the leading provider of digital digestive health solutions, today announced that Chico's FAS, Grifols and other prominent businesses have added Vivante's GIThrive platform to their benefits packages to help employees manage debilitating digestive diseases as well as to reduce corporate medical spend.

Key Points: 
  • CHICAGO, June 6, 2023 /PRNewswire/ -- Vivante Health , the leading provider of digital digestive health solutions, today announced that Chico's FAS, Grifols and other prominent businesses have added Vivante's GIThrive platform to their benefits packages to help employees manage debilitating digestive diseases as well as to reduce corporate medical spend.
  • GIThrive addresses these issues by providing a comprehensive virtual platform where members can access everything they need to manage their digestive health in one place, 24/7.
  • Employers also benefit from claims filing handled by Vivante and a fees-at-risk structure based on a reduction in medical claims.
  • "These new client adoptions highlight the value that companies see in GIThrive's ability to help employees take control of their digestive health," said Vivante Health CEO Bill Snyder.